DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Claim Rejections - 35 USC § 112
The following is a quotation of the first paragraph of 35 U.S.C. 112(a):
(a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention.
The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112:
The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention.
Claim 21-28 is rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. The claims require a composition comprising dofeltilide, water at pH of 6-7 and suitable for intravenous administration. Specification provides examples of dofeltilide compositions stable at RT:
Example 2 – pH=5
Example 3 – pH=4.46
Example 4 – pH=7.25
Examples also provide Examples A-K of formulations within the claimed pH range. Paragraph [0063] states that those formulations are unstable as an intravenous Dofeltilide formulation. Since the specification does not exemplify formulations within the scope of claims 21-28 and exemplifies 11 formulations that are not suitable for IV administration of Dofeltilide, Examiner concludes that applicants were not in possession of the claimed invention at the time of filing.
Claim Rejections - 35 USC § 103
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
Claims 21-28 is/are rejected under 35 U.S.C. 103 as being unpatentable over Zelewski (Cleveland Clinic Pharmacotherapy Update, 2000, 3(4) pages 1-3; cited in IDS) in view of Coz et al (Clinical Pharmacology and Therapeutics, 1995, 57(5), 533-542 cited in IDS) and Wada et al (Clin Pharmacokinet, 1998, 35(1), 1-7; cited in IDS).
Scope of prior art
Zelewski teaches Dofetilide as an antiarrhythmic agent and describes dosing protocol and considerations that are to be taken into account when determining a maintenance dose of the drug. Zelewski teaches that a patient admitted to the hospital is kept under observation for at least 72 hours which corresponds to the time required to reach steady state and is consistent with the information applicants provided in the description (page 1).
Zelewski teaches reducing the dose if QTc increase after first dose is greater than 15% or above 500msec (550 for patients with ventricular conduction abnormalities (page 2; page 3 “Dosing, administration and monitoring”)
Zelewski teaches adjusting the initial dose based on renal function with 500µg for patients with > than 60mL/min; 250 µg for 40-60mL/min and 125 µg for 20-40 mL/min (page 2-3, Table 1).
Zelewski teaches the criticality of monitoring the patients via electrocardiography (page 2).
Zelewski teaches dofetilide treatment is recommended for subjects with AF (page 1)
Ascertaining the difference
The teachings of Zelewski represent an art accepted standard in initiating treatment with Dofetilide. This protocol is taught in numerous other prior art documents and is described in the instant specification as an art accepted methodology. The difference between the teachings of Zelewski and the instant claims is as follows:
Using the protocol of the art the patient is kept in the hospital for at least 72 hours which corresponds to the time required to reach steady state. Instant claims are directed to the same monitoring and inclusion parameters, however while art only teaches maintenance dosing instant claims are directed to intravenous infusion of Dofeltifide followed by the first maintenance dose. This represents a dosing schedule which comprises a loading dose followed by maintenance dosing.
The issues to be resolved are:
1) would it have been obvious to one skilled in the art to administer a loading doze of Dofeltifide;
2) Would it have been obvious to select intravenous administration instead of oral administration of the drug for the loading dose.
3) Would it have been obvious to administer an IV infusion of 10-1000 µg/mL at a dose of 1.8-3.0µg/kg as a formulation at neutral pH.
Secondary references
Coz et al teach that Dofeltifide can be administered via oral and intravenous routes and both routes result in high bioavailability and increase QTc interval in the subject (abstract). Both methods result in similar CL and half-life (page 539 column 2 paragraph 1). Coz also teaches that infusion over a 10 minute time period is common (page 539, Discussion, paragraph 2).
Wada et al teach that in intravenous loading dose is given to rapidly achieve desired drug concentration in the blood (steady state) (abstract). Wada also teaches methods directed to calculating the appropriate loading dose for a drug based on the volume of distribution and desired steady state concentration (page 2 right column) and that loading dose can be safely administered using the specified parameters (conclusion).
Obviousness
One skilled in the art prior to the effective filing date of the instant application would have found it obvious to shorten the time required to achieve steady state concertation of dofeltifide by administering a loading dose followed by the art recommended maintenance doing schedule. Initiating the dosing protocol when administering dofeltilide is described by Zelewski. Zelewski teaches all of the limitations of the instant claims including dosing schedule and dosing adjustments based on QTc, renal function and ventricular conduction abnormalities. Zelewski also teaches the importance of monitoring the patient via electrocardiography and the required 72 hour hospital stay until a steady state is achieved.
One skilled in the art would have been motivated to shorten the required hospital stay of the patient by arriving at a steady state in a shorter time period. Wada teaches that a shorter time period to achieve steady state concentration of a drug can be accomplished by utilizing a loading dose which is higher than the usual maintenance dose. Wada teaches that the loading dose is different for every drug due to varying pharmacokinetics properties but suggests a common formula based on desired steady state drug concertation and the volume of distribution of the drug that can be used to calculate the proper loading dose. In view of Wada one would have found it obvious to administer a loading dose of dofeltilide to a subject in order to shorten the time required to achieve steady state and thereby lessen the hospital stay of the patient. One would have used Wada’s formula in order to determine the appropriate loading dose.
With regards to intravenous administration, one would have found it obvious to use intravenous administration as a loading dose because it is known from Coz that both oral and intravenous administrations result in increase in QTc and both methods have high bioavailability. However with intravenous administration QTmax is reached quicker since the drug is infused directly into the blood.
Prolonged hospital stays are expensive which serves as motivation to modify the teaching Zelewski in a manner that would shorten the time spent in a hospital. The teachings of Wada suggest that the hospital stay can be shortened by decreasing the time required for arriving at steady state dofeltilide concertation. Wada provides expectation of success in the conclusion. Wada states that the loading dose calculated using the described method will rapidly achieve the target concertation without unexpected adverse effects.
Regarding the time intervals between measurements of QTc: One skilled in the art would have found it obvious to determine the optimal time periods to measure QTc. Since QTc is used to determine dose adjustment and is correlated to the side effects of dofeltilide administration it would be necessary to measure it often in order to safely initiate treatment. While the instantly claimed “every 30 minutes until dofeltilide is titrated” is not explicitly recited, one skilled in the art would have found it obvious to determine the measurement increments.
With regards to the pH and concertation of the injected formulation:
It would have been obvious to inject a formulation with a neutral pH in order to avoid irritation. It would have been obvious to determine the concertation of the formulation based on the amount to be delivered and time period over which infusion takes place. Applicants can overcome this by showing criticality of the claimed concentration.
Double Patenting
The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).
A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b).
The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13.
The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer.
Claims 21-28 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1, 3, 5, 6, 7, 8, 13, 14 of U.S. Patent No. 11,364,213. Although the claims at issue are not identical, they are not patentably distinct from each other. Like current claims, those of the ‘213 patent are directed to a method of rapidly titrating and chronically administering dofeltilide. The method comprises infusing intravenously dofeltilide followed by oral administration of 500 µg. The oral dose is reduced based on the QTc and GFR rate. The iv administration is in an amount sufficient to provide a serum concertation equivalent to predicted maximal steady state concertation. This amount is further limited to 3 µg/kg in claims 5 and 13. While ‘213 does not recite the concertation of the administered iv formulation, it would have been obvious to determine the required concertation to achieve 3 µg/kg administered over 30 minutes.
Conclusion
Claims 21-28 are pending
Claims 21-28 are rejected
Any inquiry concerning this communication or earlier communications from the examiner should be directed to YEVGENY VALENROD whose telephone number is (571)272-9049. The examiner can normally be reached Mon-Fri 9am-5pm.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Amy L Clark can be reached at 571-272-1310. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/YEVGENY VALENROD/Primary Examiner, Art Unit 1628